42 completed, 17 terminated, 5 active not recruiting, 3 withdrawn. 68 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 68 | Completed 42, Terminated 17, Active not recruiting 5, Withdrawn 3, Recruiting 1 |
| Phase 1 | 8 | Completed 5, Terminated 3 |
Follow Recurrent Melanoma: new trials by email Literature Review of Recurrent Melanoma trials Research Report on Recurrent Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 150 | 2022-12-06 | 2026-10-29 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Pembrolizumab, Talimogene Laherparepvec - Advanced Melanoma, Recurrent Melanoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 43 | 2018-06-05 | 2026-05-20 |
| Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Conventional Surgery, Ipilimumab, Laboratory Biomarker Analysis - Cervical Carcinoma, Esophageal Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2017-11-03 | 2018-10-03 | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-26 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
| Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2015-01-01 | 2020-07-27 | |
| Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations trametinib, laboratory biomarker analysis, pharmacological study - Recurrent Melanoma, Stage IIIB Melanoma | Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 9 | 2015-01-01 | 2021-05-28 |
| High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery aldesleukin, ipilimumab, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Terminated | CINJRegulatory | 9 | 2014-11-26 | 2023-07-18 |
| Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma ipilimumab, stereotactic radiosurgery, laboratory biomarker analysis - Liver Metastases, Lung Metastases | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 8 | 2014-09-05 | 2024-05-21 |
| Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic cytology specimen collection procedure, MEK 162 therapy or molecularly targeted therapy, therapeutic procedure - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Completed | Yale University | 49 | 2014-05-01 | 2020-01-02 |
| Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Melanoma, Stage IV Skin Melanoma | Phase 2 | Terminated | University of Washington | 23 | 2014-03-01 | 2020-02-13 |
| Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Epacadostat, MELITAC 12.1 Peptide Vaccine - Mucosal Melanoma, Recurrent Melanoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 11 | 2013-09-13 | 2018-06-08 |
| Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Ipilimumab, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b - Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 88 | 2013-03-25 | 2026-07-21 |
| Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery dabrafenib, trametinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced) | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 13 | 2013-01-01 | 2017-06-23 |
| Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib Akt inhibitor MK2206, selumetinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2012-01-01 | 2014-06-18 |
| Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery axitinib, laboratory biomarker analysis - Extraocular Extension Melanoma, Metastatic Intraocular Melanoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 25 | 2012-01-01 | 2018-05-09 |
| Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma laboratory biomarker identification and analysis, biopsy, immunohistochemistry/tissue microarrays - Recurrent Melanoma, Stage IIIc Melanoma | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 12 | 2011-10-01 | 2016-05-30 |
| Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma NA17.A2 Peptide Vaccine, Recombinant MAGE-3.1 Antigen, Recombinant Interleukin-12 - Recurrent Melanoma, Stage IV Skin Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 10 | 2011-02-01 | 2016-10-24 |
| Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Aldesleukin, Laboratory Biomarker Analysis, Ziv-Aflibercept - Metastatic Melanoma, Recurrent Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 84 | 2011-01-18 | 2019-05-10 |
Showing 20 of 68. Sign in to see all of them.
Melanoma (68) · Uveal Melanoma (8) · Neoplasms (5) · Skin Neoplasms (5) · Brain Neoplasms (3) · Breast Neoplasms (3) · Breast Neoplasms, Male (2) · Carcinoma, Renal Cell (2) · Colonic Neoplasms (2) · Esophageal Neoplasms (2) · Glioma (2) · Lymphoma, Non-Hodgkin (2) · Neuroblastoma (2) · Neuroectodermal Tumors, Primitive, Peripheral (2) · Osteosarcoma (2)
Neoplasms by Histologic Type (68) · Neoplasms by Site (68) · Neoplasms, Germ Cell and Embryonal (68) · Neoplasms, Nerve Tissue (68) · Neuroectodermal Tumors (68) · Neuroendocrine Tumors (68) · Nevi and Melanomas (68) · Skin Diseases (68) · Skin and Connective Tissue Diseases (68) · Neoplasms (63) · Skin Neoplasms (63) · Eye Diseases (8) · Eye Neoplasms (8) · Uveal Diseases (8) · Uveal Neoplasms (8)
CTLA-4 Antigen (8) · Ipilimumab (8) · Biopsy (7) · Interleukin-2 (7) · aldesleukin (7) · Bevacizumab (5) · Cyclophosphamide (4) · Immunohistochemistry (4) · Nivolumab (4) · Sirolimus (4) · temsirolimus (4) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (3) · AZD 6244 (3) · Disulfides (3) · Immunoglobulin G (3)
National Cancer Institute (NCI) (48) · Fred Hutchinson Cancer Center (4) · Vanderbilt-Ingram Cancer Center (3) · Abramson Cancer Center at Penn Medicine (1) · Alliance for Clinical Trials in Oncology (1) · CINJRegulatory (1) · Case Comprehensive Cancer Center (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · University of Southern California (1) · University of Washington (1) · Vical (1)
United States (65) · Canada (3) · Puerto Rico (2) · Guam (1)
Thomas Gajewski (5) · Ahmad Tarhini (3) · Craig Slingluff (2) · Kim Margolin (2) · Patrick Hwu (2) · Paul Chapman (2) · Siwen Hu-Lieskovan (2) · Svetomir Markovic (2) · William Carson (2) · Alexander Shoushtari (1) · Amy Weise (1) · Anna Pavlick (1) · Antoni Ribas (1) · Aude Chapuis (1) · Barbara A. Pockaj, MD (1)
PMID 20098694, PMID 20967484, PMID 21642685, PMID 23228035, PMID 23620404, PMID 24047116, PMID 24464266, PMID 24817603, PMID 25250858, PMID 25369488, PMID 25797743, PMID 26586415, PMID 27269940, PMID 27368067, PMID 31401903, PMID 31998643, PMID 32192573, PMID 32463741, PMID 32641862, PMID 32692450, PMID 33048619, PMID 33861486, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39342463, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40865033, PMID 41066729, PMID 42853672
N01CM62206 (4), U10CA031946 (4), P30CA008748 (3), U10CA032102 (3), U10CA180820 (3), K12CA076930 (2), N01CM00070 (2), N01CM00071 (2), N01CM62201 (2), N01CM62203 (2), N01CM62205 (2), N01CM62209 (2), P30CA014599 (2), P30CA033572 (2), U10CA021115 (2)